Focus: Inmunotek is a Spanish biotechnology company specializing in allergen extracts and immunotherapy treatments for allergy and immunology indications. The company operates a diversified pipeline focused on allergic rhinitis, mite allergies, and emerging infectious disease vaccines.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
Stable — net +2 jobs in 30d
4 added, 2 removed. Backfill posture.
Inmunotek offers exposure to immunotherapy science and European regulatory experience, but limited hiring and opaque financials make it a higher-risk, niche-specialist opportunity best suited for domain experts willing to accept startup-scale volatility.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Inmunotek
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Inmunotek's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles